- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04874831
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
November 10, 2021 updated by: 4SC AG
A Phase II, Open Label, Multicenter Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed written informed consent.
- Age 18 years at signature of Informed Consent Form (ICF).
Histologically proven MCC.
- Confirmation of the diagnosis by immune-histochemistry as per standard at the institution, including (but not limited to) CK20 and TTF-1.
- Patients must have metastatic or distally recurrent disease; Ml status must be confirmed at entry.
- Patients must not have received any prior systemic treatment for metastatic MCC. Prior treatment in the adjuvant setting (no clinically detectable disease; no metastatic disease) will be allowed, if the end of the treatment occurred at least 6 months prior to study entry, i.e. signing ICF.
- Fresh biopsy or archival tumor tissue (not older than 3 months) from an unirradiated lesion.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry.
- Estimated life expectancy of more than 12 weeks.
- Disease must be measurable with at least one unidimensional measurable lesion by RECIST vl.l (including skin lesions).
Adequate hematological and organ function defined by the following parameters:
Adequate hematological function defined by
- White blood cell count (WBC) > 3000/pl
- Absolute Neutrophil Count (ANC) > 1500/pl
- Lymphocyte count > 500/pl
- Hemoglobin (Hb) > 9 g/dl (or > 5.6 mmol/L), may have been transfused
- Platelet count > 100.000/pl
Adequate hepatic function defined by
- Serum total bilirubin < 1.5 x ULN
- ALT and/or AST < 1.5 x ULN
Adequate renal function defined by
• eGFR > 60 ml/ min (as per Cockcroft-Gault formula)
- Highly effective contraception for both male and female subjects if the risk of conception exists. Female patients of childbearing potential must have a negative urine or serum pregnancy test before receiving the first dose of study medication and must comply with contraception methods as requested by the study protocol.
Exclusion Criteria:
- Participation in another interventional clinical study within the past 30 days (participation in observational studies is permitted)
- Concurrent treatment with a non-permitted drug.
- Prior therapy with any histone deacetylase (HDAC) inhibitor or antibody/drug targeting T cell coregulatory proteins (immune checkpoints) such as anti-programmed death 1 (PD-1), antiprogrammed death-ligand 1 (PD-L1) or anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody.
- Concurrent anti-cancer treatment (for example, cytoreductive therapy, radiotherapy, immune therapy, or cytokine therapy except for erythropoietin). Radiotherapy administered to superficial lesions is not allowed if such lesions are considered target lesions in the efficacy evaluation or may influence the efficacy evaluation of the study treatment.
- Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from surgery.
- Concurrent systemic therapy with steroids or other immunosuppressive agents (e.g. methotrexate, azathioprine, interferons, mycophenolate, anti-TNF agents and other), or the use of any investigational drug within 28 days before the start of study treatment. Short-term administration of systemic steroids e.g. for allergic reactions or the management of immune-related adverse events [irAE] while on study is allowed. Also, patients requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for purpose of hormonal replacement and at doses < 10 mg or equivalent prednisone per day.
- Conditions requiring systemic anti-arrhythmic therapy known to prolong QT/QTc interval, patients with QTcF interval >480 msec on at least 2 separate and consecutive ECGs at screening or a medical history of long-QT-Syndrome.
- Patients with active central nervous system (CNS) metastases are excluded and a brain CT/MRI will be required during screening if not performed within 6 weeks prior to the planned start of the study treatment. Subjects with a history of treated CNS metastases (by surgery or radiation therapy) are not eligible unless they have fully recovered from treatment, demonstrated no progression for at least 2 months, and do not require continued steroid therapy.
- History of or concurrent malignancies, except the malignancy is clinically insignificant, no systemic treatment is or has been required for the last 6 months, and the patient is clinically stable
- Prior organ transplantation (including allogeneic stem-cell transplantation).
- Any active gastrointestinal disorder that could interfere with the absorption of domatinostat characterized by malabsorption or inability to swallow tablets as per judgment of the Investigator.
- Positive testing for HIV or known AIDS or HBV or HCV infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening is positive).
- Active or history of any autoimmune disease (except for patients with vitiligo) or immune-diseases that required treatment with systemic immune modulating drugs.
- History or current evidence of clinically relevant allergies or hypersensitivity, which includes known or suspected intolerabilities attributed to domatinostat or avelumab or to constituents of the domatinostat tablets or avelumab infusion and known severe hypersensitivity reactions (Grade 3) to monoclonal antibodies.
- Persisting toxicity related to prior therapy Grade > 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0; however, sensory neuropathy Grade < 2 will be acceptable.
- Pregnancy or lactation period.
- Known or suspected alcohol or drug abuse.
Clinically significant (i.e. active) cardiovascular and/or thromboembolic diseases:
- Cerebral vascular accident or stroke < 6 months prior to enrollment.
- Uncontrolled hypertension
- Congestive heart failure (New York Heart Association (NYHA) ClassIII or IV)
- Serious cardiac arrhythmia requiring medication (patients with status post pacemaker and/or defibrillator implantation can be included)
- Symptomatic ischemic or severe valvular heart disease
- Unstable angina pectoris or a myocardial infarction within 6 months prior to screening, i.e. signing ICF
- All other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient s tolerance to the study treatment.
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Legal incapacity or limited legal capacity.
- Administration of a live vaccine within 28 days prior to study drug administration. Live vaccines are also prohibited during study treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: domatinostat and avelumab
Single arm study of Domatinostat tablets in combination with avelumab infusion
|
domatinostat tablets and avelumab infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Objective Response (OR)
Time Frame: up to 1 year
|
Confirmed Objective Response (OR) according to RECIST vl.l, determined by independent review.
Both Complete Response and Partial Response must be confirmed by a second tumor assessment preferably at the regularly scheduled 6-weeks assessment interval, but no sooner than 4 weeks after the initial diagnosis of CR or PR.
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: up to 1 year
|
Duration of Response (DOR) according to RECIST vl.l as determined by independent review.
|
up to 1 year
|
Durable Response (DR)
Time Frame: up to 1 year
|
Durable Response (DR) according to RECIST vl.l, defined as objective response (CR or PR) determined by independent review with duration of at least 6 months.
|
up to 1 year
|
Overall Survival (OS)
Time Frame: approx 3.5 years
|
Overall Survival (OS) time, defined as the time from the first administration of study treatment until death due to any cause determined by the Investigator.
|
approx 3.5 years
|
Progression Free Survival (PFS)
Time Frame: approx. 3 years
|
Progression Free Survival (PFS) according to RECIST vl.l, defined as the time from first dosing (Day 1) to the date of PD or death from any cause (whichever comes first) as determined by independent review.
|
approx. 3 years
|
Disease Control (DC)
Time Frame: up to 1 year
|
Disease Control (DC) according to RECIST vl.l, defined as the proportion of patients with either an objective response (CR, PR) or stable disease (SD), as determined by independent review.
|
up to 1 year
|
RECIST vl.l response
Time Frame: up to 1 year
|
RECIST vl.l responses at 6 and 12 months after start of study treatment as determined by independent review.
|
up to 1 year
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0
Time Frame: approx. 3 years
|
number, frequency, duration and severity of AEs
|
approx. 3 years
|
Correlation of biomarker expression to efficacy
Time Frame: up to 1 year
|
Correlation of ORR, DOR, DR, DC and PFS to biomarker expression determined by immunohistochemistry.
|
up to 1 year
|
Anti-drug-antibodies (ADAs)
Time Frame: up to 1 year
|
Anti-drug-antibodies (ADAs) treatments.
|
up to 1 year
|
Health related Quality of Life determined by the questionnaire FACT-M
Time Frame: up to 1 year
|
The impact of treatment on the patient's QoLwill be assessed with the questionnaire "Functional Assessment of Cancer Therapy - Melanoma (FACT-M)" where QoL is assessed on a scale 0-240 (higher score means better status of health)
|
up to 1 year
|
Plasma concentration of domatinostat and avelumab
Time Frame: up to 1 year
|
Single trough values of domatinostat and avelumab at pre-defined time points
|
up to 1 year
|
Health related Quality of Life determined by the questionnaire EQ-5D-5L
Time Frame: up to 1 year
|
The impact of treatment on the patient's QoLwill be assessed with the questionnaire "EQ-5D-5L" which is a multi attribute utility instrument for measuring health-related QoL as EQ5D index with a score 0-1 (higher score means better status of health)
|
up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
November 1, 2021
Primary Completion (ANTICIPATED)
September 1, 2025
Study Completion (ANTICIPATED)
September 1, 2025
Study Registration Dates
First Submitted
April 15, 2021
First Submitted That Met QC Criteria
April 30, 2021
First Posted (ACTUAL)
May 6, 2021
Study Record Updates
Last Update Posted (ACTUAL)
November 18, 2021
Last Update Submitted That Met QC Criteria
November 10, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- DNA Virus Infections
- Tumor Virus Infections
- Neuroendocrine Tumors
- Polyomavirus Infections
- Carcinoma, Neuroendocrine
- Carcinoma
- Carcinoma, Merkel Cell
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Avelumab
Other Study ID Numbers
- 4SC-202-4-2019
- 2019-003575-19 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Merkel Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)CompletedRecurrent Merkel Cell Carcinoma | Stage III Merkel Cell Carcinoma AJCC v7 | Stage IV Merkel Cell Carcinoma AJCC v7 | Stage IIIA Merkel Cell Carcinoma AJCC v7 | Stage IIIB Merkel Cell Carcinoma AJCC v7United States
-
Melanoma and Skin Cancer Trials LimitedRecruitingNeuroendocrine Tumors | Merkel Cell Carcinoma | Merkel Cell Carcinoma, Stage I | Merkel Cell Carcinoma, Stage II | Merkel Cell Carcinoma, Stage III | Carcinoma Neuroendocrine SkinAustralia, New Zealand
-
University of WashingtonEMD SeronoActive, not recruitingStage III Merkel Cell Carcinoma AJCC v8 | Stage IIIB Merkel Cell Carcinoma AJCC v8 | Stage IIIA Merkel Cell Carcinoma AJCC v8United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
National Cancer Institute (NCI)SuspendedPathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8United States
-
University of WashingtonIncyte CorporationRecruitingMerkel Cell Carcinoma | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8United States
-
ImmunityBio, Inc.UnknownStage IIIB Merkel Cell Carcinoma | Stage IV Merkel Cell CarcinomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); EMD SeronoTerminatedStage IV Merkel Cell Carcinoma AJCC v7 | Merkel Cell Polyomavirus InfectionUnited States
Clinical Trials on domatinostat in combination with avelumab
-
4SC AGActive, not recruitingMerkel Cell CarcinomaSpain, Netherlands, Belgium, Germany, France, Italy
-
PfizerTerminatedNon-small Cell Lung Cancer | Urothelial CancerSpain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, Germany; 4SC AGUnknownCancer | GI CancerUnited Kingdom
-
Shen LinUnknownColorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2China
-
Aurora Health CareRecruiting
-
Peking Union Medical CollegeNot yet recruiting
-
Hunan Province Tumor HospitalNot yet recruitingNon-small Cell Lung CancerChina
-
Hunan Province Tumor HospitalNot yet recruitingNon-Small Cell Lung CancerChina
-
AkesoNot yet recruiting
-
Sun Yat-sen UniversityRecruitingPeripheral T-cell LymphomaChina